Capone, A.; Carbone, M.L.; Mastroeni, S.; Di Pietro, F.R.; Verkhovskaia, S.; Morese, R.; Melo, N.; D’Atri, S.; De Galitiis, F.; Falcone, R.;
et al. Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis. Cancers 2026, 18, 1072.
https://doi.org/10.3390/cancers18071072
AMA Style
Capone A, Carbone ML, Mastroeni S, Di Pietro FR, Verkhovskaia S, Morese R, Melo N, D’Atri S, De Galitiis F, Falcone R,
et al. Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis. Cancers. 2026; 18(7):1072.
https://doi.org/10.3390/cancers18071072
Chicago/Turabian Style
Capone, Alessia, Maria Luigia Carbone, Simona Mastroeni, Francesca Romana Di Pietro, Sofia Verkhovskaia, Roberto Morese, Nidia Melo, Stefania D’Atri, Federica De Galitiis, Rosa Falcone,
and et al. 2026. "Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis" Cancers 18, no. 7: 1072.
https://doi.org/10.3390/cancers18071072
APA Style
Capone, A., Carbone, M. L., Mastroeni, S., Di Pietro, F. R., Verkhovskaia, S., Morese, R., Melo, N., D’Atri, S., De Galitiis, F., Falcone, R., Fortes, C., Volpe, E., & Failla, C. M.
(2026). Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis. Cancers, 18(7), 1072.
https://doi.org/10.3390/cancers18071072